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Abstract 
Stem cell transplantation is a promising strategy for delayed wound healing caused by 
chemotherapy. However, the fate of stem cells under chemotherapy has not been fully 
elucidated. Herein we characterized human fetal bone marrow stromal cells (hBMSCs) 
during  wound  healing  in  mice  treated  with  cyclophosphamide  (CTX).  The  isolated 
hBMSCs  expressed  the  phenotype  of  CD11blow/CD14low/CD34low/CD45low/ 
CD29high/CD44high/CD90high/CD105high/CD146high/STRO-1low.  Following  in vitro  expo-
sure to CTX, hBMSCs showed decreased cell growth in a dose- and time-dependent 
manner, accompanied by increased expressions of collagen-I/III, and CD31. After trans-
plantation, wounds closed as early as 8 days and were positive for α-smooth muscle actin 
(α-SMA), implicating the enhanced re-epithelialization and wound contraction. Moreo-
ver, proliferating cell nuclear antigen (PCNA) and CD31 showed co-localization with 
α-SMA,  suggesting  the  differentiation  of  hBMSCs  into  epithelial  cells  and  myofibro-
blasts/fibroblasts. Taken together, our results indicate hBMSCs can accelerate wound 
healing under chemotherapy through altering their phenotypes. 
Key words: bone marrow stromal cells; delayed wound healing; cyclophosphamide; cell function 
Introduction 
Cyclophosphamide  (CTX)  is  a  common  drug 
widely used in chemotherapy. It functions by slowing 
or  blocking  cell  growth  and  compromising  the  im-
mune system's response. However, a lot of side effects 
have evolved (1). One is delayed or impaired wound 
healing, which frequently occurs in the patients un-
dergoing surgery due to long-term chemotherapy (1). 
Treatment  for  this  condition  remains  difficult  and 
largely ineffective, because the growth of cells in the 
wound  is  inhibited  (2)  and  chemotherapy  usually 
leads to myelosuppression, the latter of which further 
compromises the migration of multipotent cells from 
the bone marrow (3). 
Nevertheless, myelosuppression can be reversed 
by autologous stem cell transplantation (SCT), even 
without additional toxicity (4, 5). So does allogeneic 
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SCT (6, 7). Increasing studies indicate SCT provides a 
promising strategy for the treatment of problematic 
wounds. However, the fate of stem cells under chem-
otherapy has not been fully elucidated. 
In order to eliminate the interference from the 
transplanted  cells  themselves,  fetal  stem  cells  were 
used for transplantation because the proliferation and 
differentiation potentials of fetal stem cells are supe-
rior to the adult ones (8). Moreover, the state of stem 
cells is a prerequisite and basis for their application. 
Previous studies reported that old patients had high 
risks in chemotherapy (9) and the wound healing was 
compromised with the increase of age (10). These may 
be attributed to the changes in the functional status of 
stem cells. Therefore, fetal stem cells are suitable cells 
for clarifying the influences of CTX on cell functions. 
Herein,  the  growth  and  proliferation,  gene  ex-
pression,  multipotency  and  phenotype  of  cultured 
hBMSCs were compared with those incubated with 
CTX.  Then,  hBMSCs  were  transplanted  into  the 
full-thickness  skin  wound  in  the  severe  combined 
immune  deficiency  (SCID)  mice  conditioned  with 
high-dose CTX and wound healing was assessed by 
cell proliferation and dermal regeneration.  
Materials and Methods 
Cell culture and characterization 
This  study  was approved  by the Ethical Com-
mittee of Fourth Military Medical University and the 
informed consent was obtained from each parent be-
fore study. Bone marrow was collected from the ante-
rior superior iliac spine of two 7-month-old human 
fetuses  from  induced  abortion  and  nucleated  cells 
were  isolated  using  Percoll  (1.073  g/ml;  GE 
Healthcare, UK) density gradient centrifugation. Nu-
cleated cells were seeded in T25 dishes at a density of 
1×105 cells/cm2 and maintained in MesenPRO RSTM 
medium  (Gibco,  USA)  at  37℃  in  a  humidified  at-
mosphere with 5% CO2. The medium was refreshed 
every 3 days. When cell confluence reached 80%, cells 
were harvested and passaged. Cells from passage 3 to 
5 were used for the following experiments. 
Flow cytometry: aliquots containing 105 hBMSCs 
were  incubated  at  4℃  for  1  h  with  100  μl  of 
FITC-conjugated mouse anti-human mAb to CD11b, 
CD14,  CD29,  CD34,  CD45,  or  CD90  (eBioscience, 
USA),  STRO-1,  rabbit  anti-human  pAb  CD105  and 
isotype-matched  control,  independently.  The  cells 
treated with rabbit anti-human CD105 mAb were in-
cubated  with  FITC-conjugated  goat-anti-rabbit  IgG 
(Santa  Cruz,  USA).  After  washing  twice  and 
re-suspension, quantitative fluorescence analysis was 
performed  using  a  FACS  Calibur  cytometer  (Beck-
man-Coulter, USA). Aliquots containing 106 hBMSCs 
were analyzed for cell cycle after 1 week of culture.  
The  hBMSCs  of  passage  3  were  seeded  in  a 
12-well plate at a density of 1×104 cells/cm2. When the 
cell  confluence  reached  80%,  the  medium  was  re-
placed with osteogenic (α-MEM, 7% fetal calf serum 
[FCS],  0.1  μM  dexamethasone,  10  mM 
β-glycerolphosphate  and  50  mg/L  ascor-
bate-2-phosphate)  or  adipogenic  induction  medium 
(α-MEM, 7% FCS, 0.25 μM dexamethasone, 100 μM 
indomethacin, 0.5 mM 3-isobutyl methylxanthine and 
10 mg/L insulin). The media were refreshed every 3 
days. After 2 weeks, cells were stained with Alizarin 
Red S and Oil-red O (Sigma, USA) to detect the min-
eralized nodules and neutral lipid vacuoles.  
Cell proliferation assay: hBMSCs were seeded in 
a 96-well plate at a density of 1200 cells/well, and cell 
proliferation  was  determined  by  using  methylte-
trazolium (MTT) assay after 1-9 days of culture. 
Real-time PCR 
Total  RNA  were  extracted  from  the  cultured 
hBMSCs  using  RNeasy  extraction  kit  (Invitrogen, 
USA) and first-strand cDNA synthesis was performed 
according to the manufacturer’s instructions (TaKaRa, 
Japan).  Primers  were  as  follows:  β-actin: 
TGGCACCCAGCACAATGAA  (forward),  CTAAGT 
CATAGTCCGCCTAGAAGCA (reverse); Type I col-
lagen  (Col-I):  CCCGGGTTTCAGAGACAACTTC 
(forward),  TCCACATGCTTTATTCCAGCAATC  (re-
verse);  Type  III  collagen  (Col-III): 
CCACGGAAACACTGGTGGAC  (forward), 
GCACATCAAGGACATCTTCAGGA  (reverse); 
CD31:  AGGCCCTCAAGGTTTCCAAGG  (forward), 
CCAGACCATTGTGTCCCCTAA  (reverse);  KRT14 
(CK14):  AACTGCTCGCTCGCTCACCT  (forward), 
AGGAGCCCTTCATGGAGCTG  (reverse);  KRT17 
(CK17): GCTGGAGGTGAAGATCCGTGA (forward), 
ATTGTCCACGGTGGCTGTGA  (reverse);  KRT19 
(CK19):  CTGAGTGACATGCGAAGCCAATA  (for-
ward),  CAGTAACCTCGGACCTGCTCATC  (re-
verse).  
Real-time PCR was performed with an iQ5 Re-
al-Time PCR Detection System (Bio-Rad Laboratory, 
USA) by using SYBR® Green PCR Master Mix (Ap-
plied Biosystems, USA) according to the manufactur-
er’s instructions. The thermocycling parameters were 
optimized as follows: pre-denaturation at 95℃ for 30 
sec, 40 cycles of denaturation at 95℃ for 10 sec, an-
nealing at 60℃ for 20 sec, extension at 95℃ for 1 min 
and a final extension at 60℃ for 1 min. PCR products 
were quantified with the Bio-Rad iQ5 Optical System 
Software and the mRNA expressions of target genes 
were normalized by that of β-actin. Int. J. Biol. Sci. 2011, 7 
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Characterization of CTX treated hBMSCs  
The hBMSCs of passage 3 were seeded in 6-well 
plates at a density of 1×104 cells/cm2. After culture 
overnight, CTX was added into the media at the final 
concentration  of  20  mg/L  (low-dose)  or  200  mg/L 
(high-dose).  Then,  the  cell  proliferation,  phenotype, 
cell cycle, multipotency, and gene expressions were 
analyzed.  
Wound preparation and transplantation 
Twenty-five  SCID  mice  were  divided  into  5 
groups: control group, CTX group, CTX+Col-I group, 
CTX+Col-I+hBMSCs group and CTX+hBMSCs group. 
SCID mice in the latter 4 groups were injected with 
high-dose CTX subcutaneously at 24 h before trans-
plantation. Mice were anesthetized intraperitoneally 
with  1%  sodium  pentobarbital,  and  skin  was  pre-
pared. Then, a 1.5-cm2 full-thickness wound including 
the panniculus carnosus muscle was made on the mid 
back. In the CTX+Col-I+hBMSCs group, 106 hBMSCs 
were labeled with fluorescent dye PKH-26 and mixed 
with type I collagen (Sigma, USA). Then the cell sus-
pension  was  transplanted  into  the  wound  bed  fol-
lowed by wound closure. In the CTX+hBMSCs group, 
106  PKH-26  labeled  hBMSCs  were  re-suspended  in 
300 μl of normal saline, which were injected into the 
wound bed and marginal area. Finally, the wounds 
were covered with transparent semiocclusive dress-
ings (Tegaderm, 3M, USA) in all groups. 
Wound observation 
Wound healing was observed at the postopera-
tive day 8 and 16. All wounds were healed and scars 
were observed on day 21. Mice were euthanized and 
the entire wounds including the normal skin 2 mm 
away from the wound margin were excised and fixed 
in cold acetone and 10% formalin for the following 
experiments. 
Immunohistochemistry 
Tissues  were  cut  into  5-μm  sections.  After  de-
paraffinization and hydration, antigen retrieval was 
performed  and  endogenous  peroxidase  was  inacti-
vated  with  3%  H2O2.  Sections  were  blocked  with 
normal goat serum for 30 min and then treated with 
mouse-anti-human  mAb  proliferating  cell  nuclear 
antigen (PCNA), CK14, CK17, CK19 and Col-I, rab-
bit-anti-human  pAb  CD31,  α-smooth  muscle  actin 
(α-SMA),  or  matrix  metalloproteinases-1  (MMP-1) 
(Abcam,  UK)  at  37℃  for  1  h.  After  treatment  with 
secondary  antibody,  these  sections  were  visualized 
using DAB kit (EnVisionTM Detection system, DAKO, 
Denmark),  followed  by  counterstaining  with  hema-
toxylin  and  observation  under  a  light  microscope. 
Primary antibodies were replaced with PBS serving as 
negative controls. 
Immunofluorescence double staining  
Cryosections (8 μm in thickness) were fixed with 
cool  acetone  and  blocked  with  serum.  For  double 
staining,  the  primary  antibodies  were  rabbit  an-
ti-human  CD31  and  anti-human  α-SMA  pAbs,  the 
second  antibodies  used  were  mouse  anti-human 
PCNA, CK14 and CK17 mAbs, and TRITC-conjugated 
goat-anti-rabbit  IgG  and  FITC-conjugated  goat-anti- 
mouse IgG were used as fluorescent antibodies. After 
incubation with primary antibodies overnight at 4℃, 
TRITC-conjugated antibody was added followed by 
incubation at 37℃ for 1 h, and then FITC-conjugated 
antibody was added followed by incubation at 37℃ 
for 1 h. Finally, Hoechst33342 was used for counter-
staining. Sections were visualized using a fluorescent 
microscope (Olympus, Japan). Images were acquired 
with the DP Manager software, and processed with 
Adobe Photoshop. 
Statistical analysis 
Statistical  analysis  was  performed  with  SPSS 
version 13.0 statistic software package. Comparisons 
between  two  groups  were  done  by  using  the  inde-
pendent samples t test. A value of P<0.05 was con-
sidered statistically significant. 
Results 
Decreased growth and proliferation of hBMSCs 
after CTX treatment 
After 7 days, there was no obvious morphologi-
cal alterations and cell death after low and high dose 
CTX treatment (Fig. 1a). Some adherent cells showed 
elongated  morphology,  transparent  cell  body  and 
favorable light refraction when compared with con-
trol  group  (Fig.  1b).  hBMSCs  incubated  with  CTX 
showed decreased growth from day 1 to day 7. On 
day 9, hBMSCs growth was significantly inhibited in 
the high-dose CTX group (P<0.05) (Fig. 1c). Cell cycle 
analysis revealed the proportion of cells in the G2/S 
phase was 13.2% under normal condition, 5.6% after 
low-dose CTX treatment and 4% after high-dose CTX 
treatment. In particular, the percentage of cells in S 
phase was remained at the same level (4.8% and 4.7%) 
in the former two groups and 2.2 in the latter one (Fig. 
1d). These results indicate the growth and prolifera-
tion of stem cells is suppressed due to the cytotoxicity 
of chemotherapy which is a dose and time dependent 
manner, but the DNA synthesis is only inhibited by 
high-dose CTX treatment. Therefore, high-dose CTX 
was used for further study. Int. J. Biol. Sci. 2011, 7 
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Fig. 1. Decreased growth and proliferation of hBMSCs after CTX treatment. (a) There was no obvious morphological al-
terations and cell death 7 days after low and high dose CTX treatment. (b) Some adherent cells showed elongated ap-
pearance, and transparent cell body and had light refraction. (c) hBMSCs treated with CTX of different doses showed de-
creased growth from day 1 to day 7. Until 9 days after high-dose CTX treatment, hBMSCs showed significantly decreased 
growth when compared with control group (*P<0.05 vs 20 and 200 mg/kg groups). (d) Cell cycle analysis revealed the 
proportion of cells in G2/S phase was 13.2% under normal condition, 5.6% after low-dose CTX treatment and 4% after 
high-dose CTX treatment. In particular, the proportion of cells in S phase was remained at the same level (4.8% and 4.7%) in 
the former two groups and 2.2% in the latter one. Bar=50 μm. d=day(s). Int. J. Biol. Sci. 2011, 7 
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Alterations in phenotype, and multipotency after 
CTX incubation 
The expressions of cell markers between cells in 
the control group and those incubated with high-dose 
CTX are shown in Fig. 2. Results showed the signifi-
cantly decreased expressions of hematopoietic mark-
ers CD11b (from 5.4% to 1.3%), CD14 (from 6.3% to 
1.5%), CD34 (from 5.7% to 1.5%) and CD45 (from 6.8% 
to 1.4%) in the high-dose CTX group. The expressions 
of mesenchymal markers CD29 (from 100% to 99.9%), 
CD105  (from  100%  to  97.1%),  CD90  (from  100%  to 
100%) remained stable, but that of STRO-1 increased 
(from 5.2% to 7.4%). Of note, there was significantly 
decreased  expression  of  endothelial/mesenchymal 
marker CD146 (from 75% to 32.3%). These findings 
indicate the growth and proliferation of progenitors 
derived from hematopoietic lineage  are suppressed, 
but those from mesenchymal lineage are not signifi-
cantly influenced, except for cells expressing CD146 
which is also concerned as an endothelial cell marker. 
We  speculate  that  hematopoietic  and  endothelial 
characteristics are inhibited, which is different from 
the maintenance of mesenchymal features under this 
condition. 
After  induction,  mineralized  nodules  and  neu-
tral lipid vacuoles were found. After incubation with 
CTX,  there  was  a  significant  increase  of  cell  death, 
especially  after  adipogenic  treatment.  After  two 
weeks  of  treatment,  Alizarin  Red  S  and  Oil  red-O 
staining  showed  obvious  osteogenesis  but  impaired 
adipogenesis, which may be attributed to the increase 
of CTX dose (Fig. 2b).  
hBMSCs accelerate the healing of wounds condi-
tioned with CTX 
On  day  8  and  16,  wound  healing  was  signifi-
cantly  accelerated  in  the  CTX+Col-I  group,  the 
CTX+Col-I+hBMSCs  group  and  the  CTX+hBMSCs 
group  when  compared  with  control  group,  but  de-
layed wound healing was revealed in the CTX group 
(Fig.  3a).  In  particular,  the  wound  beds  in  the 
CTX+Col-I  group  were  ulcerative  and  exudative, 
while those in the CTX+Col-I+hBMSCs group and the 
CTX+hBMSCs  group  showed  increase  of 
re-epithelialization, in which the wounds were almost 
closed on day 8. These findings indicate Col-I treat-
ment  or/and  hBMSCs  transplantation  can  improve 
the healing of wounds conditioned with CTX. 
On  day  21,  H&E  staining  revealed  complete 
re-epithelialization  in  the  healed  samples  of  all 
groups.  Two  significant  differences  were  observed. 
The  number  of  vessel-like  structures  in  the  wound 
bed was the most in the control group and the least in 
CTX+Col-I  group.  The  density  of  dermal  layer  was 
the  highest  in  CTX+Col-I+hBMSCs  group  and  the 
lowest in CTX group (Fig. 3b-f). These findings sug-
gest  impaired  angiogenesis  or  vascular  recession  at 
that moment in the CTX+Col-I group, and enhanced 
collagen  production  and/or  proliferation  of  fibro-
blasts  after  transplantation  in  the 
CTX+Col-I+hBMSCs group.  
hBMSCs proliferate in the regenerated skin and 
MMP-1 contributes to collagen degradation 
Positive staining of PCNA was observed in not 
only the wound bed, but also the margin of the healed 
tissues  in  the  CTX+Col-I+hBMSCs  group.  Positive 
staining was mainly found in the superficial papillary 
layer and deep reticular layer of dermis (Fig. 4a-c).  
However,  positive  staining  of  Col-I  was  not 
found in the wound bed (Fig. 4d), and weak staining 
of Col-I observed in the interfollicular area and deep 
reticular layer of dermis in the margin of healed tis-
sues  in  the  CTX+Col-I+hBMSCs  group  (Fig.  4e,  f). 
Similarly, negative staining of Col-I was observed in 
the wound bed (Fig. 4g) and positive staining of Col-I 
noted in both papillary and reticular layers of dermis 
in the margin of healed tissues in the CTX+hBMSCs 
group (Fig. 4h, i). These results indicate type I colla-
gen  treatment  inhibits  the  collagen  production  by 
hBMSCs,  and  the  animals  receiving  injection  of 
hBMSCs  alone  have  more  collagen  production, 
demonstrated by strong staining of Col-I in the mar-
gin. 
Real-time PCR analysis revealed the expressions 
of Col-I and Col-III were slightly decreased on day 7 
but increased on day 14 in hBMSCs incubated with 
high dose CTX. The expressions of both genes were 
significantly  increased  by  13.8  and  8.2  folds  when 
compared with that on day 0 (Fig. 4j). These results 
indicate  the  collagen  production  is  enhanced  after 
CTX treatment. 
Nevertheless,  the  results  from  PCNA  staining 
were inconsistent with those from Col-I staining. In 
order  to  explain  this  discrepancy,  MMP-1  staining 
was performed. Results showed the wound bed was 
strong positive for MMP-1, suggesting tissue remod-
eling  in  CTX+Col-I+hBMSCs  group  and 
CTX+hBMSCs  group.  Therefore,  weak  staining  of 
Col-I was probably due to collagen degradation (Fig. 
4k, l). 
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Fig. 2.  Phenotype, and multipotency after CTX treatment. (a) Decreased expressions of hematopoietic markers CD11b, 
CD14, CD34 and CD45. Expressions of mesenchymal markers CD29, CD105, CD90 were remained stable but that of STRO-1 
increased. Of note, the expression of endothelial/mesenchymal marker CD146 was significantly decreased. (b) After CTX 
treatment, there was a significant increase in cell death, especially in adipogenic groups. After 2 weeks of CTX, Alizarin Red 
S and Oil red-O staining showed active osteogenesis and impaired adipogenesis which was related to the increase of CTX 
dose. Bar=50 μm. d=day(s). Int. J. Biol. Sci. 2011, 7 
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Fig. 3. hBMSCs accelerated the healing of wounds conditioned with CTX. (a) On day 8 and day 16, wound healing was 
significantly accelerated in CTX+Col-I group, CTX+Col-I+hBMSCs group and CTX+hBMSCs group when compared with control 
group, and delayed healing was revealed in CTX group. Wound beds in CTX+Col-I group were ulcerative and exudative, while 
those in CTX+Col-I+hBMSCs group showed evident re-epithelialization. The wounds were almost closed on day 8. The wound 
healing rate in the CTX+Col-I+hBMSCs was markedly higher than that in CTX group. (b-f) On day 21, H&E staining revealed 
complete re-epithelialization in the healed tissues of all groups. The number of vessel-like structures in the wound bed was 
the most in control group and the least in CTX+Col-I group. Additionally, the density of dermal layer was the highest in 
CTX+Col-I+hBMSCs group and the lowest in CTX group. Bar=100 μm. Int. J. Biol. Sci. 2011, 7 
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Fig. 4. hBMSCs proliferated in regenerated skin and MMP-1 contributed to collagen degradation. (a-c) Positive staining of 
PCNA was observed in not only the wound bed, but also the margin of the healed tissues of CTX+Col-I+hBMSCs group. Positive 
staining was mainly found in the papillary and reticular dermis. (d-f) Negative staining of Col-I was observed in the wound 
bed,  but  weak  staining  noted  in  the  interfollicular  area  and  reticular  dermis  in  the  margin  of  healed  tissue  in 
CTX+Col-I+hBMSCs group. (g-i) Negative staining of Col-I was observed in the wound bed, but positive staining in the pa-
pillary and reticular dermis in the margin of healed tissues in CTX+hBMSCs group. (j) Real-time PCR analysis revealed the 
expressions of Col-I and Col-III were slightly decreased on day 7 and the rapidly increased on day 14. (k, l) The wound bed 
of healed tissues was strong positive for MMP-1 in both groups. Bar=100 μm. PD=papillary dermis. RD=reticular dermis. 
 
Differentiated hBMSCs expressing CD31 were in 
not only vessel-like structures, but also dermis  
Notably,  only  vessel-like  structures  were  posi-
tive  for  CD31,  a  marker  of  endothelial  cells,  in  the 
CTX group (Fig. 5a, i), and both vessel-like structures 
and  stromal  cells  were  positive  for  CD31  in  the 
CTX+Col-I+hBMSCs group (Fig. 5b, ii, iii). Moreover, 
CD31 was also noted in the dermis of the margin of Int. J. Biol. Sci. 2011, 7 
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healed  wounds  in  the  CTX+Col-I+hBMSCs  group 
(Fig. 5c). Real-time PCR analysis revealed the expres-
sion  of  CD31  was  decreased  at  early  stage  but  in-
creased at later stage in hBMSCs incubated with high 
dose  CTX  (Figure  5d).  Double  immunostaining 
showed CD31 and PCNA were co-locolized in some 
parts  of  dermis  in  CTX+Col-I+hBMSCs  group  (Fig. 
5e). These results indicate hBMSCs participate in the 
dermal  regeneration  and  some  of  them  are  derived 
from endothelial lineage. 
 
 
Fig. 5. Differentiated hBMSCs express CD31 in both vessel-like structures and dermis. (a,b) only vessel-like structures was 
positive for CD31 in CTX groups, and both vessel-like structures and stromal cells positive for CD31 in CTX+Col-I+hBMSCs 
group. (c) The dermis of the margin of healed wounds was positive for CD31 in CTX+Col-I+hBMSCs group. (d) Real-time PCR 
analysis revealed the CD31 expression was decreased at early stage followed by an increase at late stage. (e) Double 
immunostaining showed CD31 and PCNA were colocolized in some parts of the dermis. Int. J. Biol. Sci. 2011, 7 
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Fig. 6. hBMSCs differentiated into myofibroblasts. (c,g-j) a weak and uncertain staining of α-SMA was found in the wound 
bed of CTX group and positive staining in not only the wound bed but also the margin of healed tissues of CTX+Col-I+hfBMSCs 
group. (a,b,e,f) both wound bed and margin of healed tissues were negative for α-SMA in control group and CTX+Col-I group. 
(d) The wound margin of healed tissues was positive for α-SMA in CTX group. (k) Double immunostaining revealed α-SMA and 
PCNA were colocolized in dermal stroma.  
 
 
hBMSCs differentiate into myofibroblasts 
Immunostaining of α-SMA showed a weak and 
uncertain staining in the wound bed in the CTX group 
(Fig. 6c) and positive staining in not only the wound 
bed  but  the  margin  of  healed  wounds  in  the 
CTX+Col-I+hBMSCs group (Fig. 6g-j). However, the 
wound bed and margin of healed tissues were nega-
tive  for  α-SMA  in  the  control  group  and  the 
CTX+Col-I group (Fig. 6a, b, e, f), even in the margin 
of healed wounds in the CTX group (Fig. 6d). α-SMA 
is a marker of myofibroblasts and PCNA is a marker 
of cell proliferation. Double immunostaining revealed 
α-SMA  and  PCNA  were  co-locolized  in  the  dermal 
stroma (Fig. 6k). These results indicate transplanted 
hBMSCs can differentiate into myofibroblasts which 
also proliferate in the wound.  
hBMSCs incubated with CTX express CK14/17/19 
and proliferate in epidermis, hair follicles with 
simultaneous expression of CD31   
On day 7 and 14, real-time PCR showed a ten-
dency of decreasing first and increasing later in gene 
expression  of  CK14,  a  continuously  increased  ten-
dency in gene expression of CK17/19 when set the 
incubation time of 0 d as control, the increased rate of 
gene  expression  was  as  labeled  (Fig.  7a).  Strong 
Staining of PCNA in wound margin concentrated on 
the  epidermis,  hair  follicles  and  sebaceous  glands; 
CD31 was also stained positive in the marginal region 
of  CTX+Col-I+hBMSCs  group,  including  epidermis 
and hair follicles compared with that of PCNA (Fig. 
7b).  By  double  immunostaining,  CD31  and  PCNA 
were overlapped in some parts of epidermis, hair fol-
licles and dermis (Fig. 7c).  
hBMSCs differentiate into epithelial Cells with 
simultaneous expression of CD31 
Positive staining of CK14 was found in basal cell 
compartments of stratified and combined epithelia in 
the  regenerated  epidermis  and  hair  follicles  (Fig. 
8a,b). Positive staining of CK19 was found in the basal 
layer of the squamous epithelia and ductal and glan-
dular  epithelia  of  hair  follicles  (Fig.  8e,f).  Positive 
staining of CK17 was found in some parts of internal Int. J. Biol. Sci. 2011, 7 
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and surrounding area of hair follicles and minor basal 
cell epithelia (Fig. 8c,d). By double immunostaining, 
CD31 and CK14 overlapped in some parts of epider-
mis and hair follicles, and CD31 and CK17 overlapped 
in some parts of internal and surrounding area of hair 
follicles and minor basal cell epithelia (Fig. 8b). 
hBMSCs differentiate into myofibroblasts and ep-
ithelial cells 
Positive  staining  of  α-SMA  was  found  in  the 
wound  margin  in  CTX+Col-I+hBMSCs  group.  Posi-
tive staining of α-SMA was found in the minor basal 
cell compartments, glandular-like area of the epider-
mis and hair follicles other than stroma (Fig. 9a). Pos-
itive  staining  of  MMP-1  was  found  in  sebaceous 
glands,  hair  follicles  and  epidermis  in  CTX+Col-I 
group and CTX+Col-I+hfBMSCs group (Fig. 9b). By 
double  immunostaining,  α-SMA  and  PCNA  over-
lapped in dermal stroma, epidermis and hair follicles 
(Fig. 9c).  
 
 
 
Fig. 7. hBMSCs differentiate into epithelial cells. (a) On day 7 and 14, real-time PCR showed a tendency of decreasing first 
and increasing later in gene expression of CK14, a continuously increased tendency in gene expression of CK17/19 when set 
the incubation time of 0 d as control, the increased rate of gene expression was as labeled. (b) Strong Staining of PCNA in 
wound margin concentrated on the epidermis, hair follicles and sebaceous glands; CD31 was also stained positive in the 
marginal region of CTX+Col-I+hBMSCs group, including epidermis and hair follicles compared with that of PCNA. (c) By 
double  immunostaining,  CD31  and  PCNA  were  overlapped  in  some  parts  of  epidermis,  hair  follicles  and  dermis. 
Epi=epidermis. D=dermis. Fo=hair follicle. Sg=sebaceous gland. Int. J. Biol. Sci. 2011, 7 
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Fig. 8. hBMSCs differentiate into epithelial cells. (a,b) Positive staining of CK14 in basal cell compartments of stratified and 
combined epithelia in the regenerated epidermis and hair follicles. (e,f) Positive staining of CK19 in the basal layer of the 
squamous epithelia and ductal and glandular epithelia of hair follicles. (c,d) Positive staining of CK17 in some parts of 
internal and surrounding area of hair follicles and minor basal cell epithelia. (g) By double immunostaining, CD31 and CK14 
overlapped in some parts of epidermis and hair follicles, CD31 and CK17 overlapped in some parts of internal and sur-
rounding area of hair follicles and minor basal cell epithelia. Epi=epidermis. D=dermis. PD=papillary layer of dermis. 
RD=reticular layer of dermis. Fo=hair follicle. 
 
Discussion 
The optimal healing of a cutaneous wound re-
quires a well-orchestrated integration of the complex 
biological and molecular events including cell migra-
tion and proliferation, extracellular matrix deposition, 
angiogenesis,  and  remodeling  (11).  However,  these 
processes are possibly altered under chemotherapy, 
which may cause delayed or impaired wound heal-
ing. 
The  detrimental  effects  of  chemotherapy  are 
dose-dependent  and  time-relevant.  There  were  no 
significant differences in the growth and proliferation 
among cells treated with CTX of different doses from 
day 1 to day 7, but marked differences were observed 
on day 9 between low dose CTX group and high-dose 
CTX group. In vivo transplantation of hBMSCs con-
sistently  demonstrated  the  accelerated  wound  heal-
ing, and the wounds were almost completely closed 
on  day  8.    Therefore,  it  seemed  that  CTX  was  not 
harmful to the transplanted hBMSCs within 7 days.  
Isolated hBMSCs contain mixed populations of 
hematopoietic  and  mesenchymal  cells.  The  expres-
sions of hematopoietic markers CD11b, CD14, CD34 
and CD45 were decreased after CTX treatment, which 
was consistent with previous reports that hematotox-
icity represented a major side effect on stem cells (12). 
The  decreased  expression  of  hematopoietic  markers 
possibly  implied  the  growth  inhibition  of  macro-
phages/monocytes  (CD11b+/CD14+low/CD34+/ 
CD45+), which compromises the infiltration of mac-
rophages/monocytes  into  the  wound.  Macrophag-
es/monocytes  are  pivotal  to  the  wound  healing, 
functioning not only as director cells, but as phago-
cytes in addition to producing chemoattractants and 
growth factors which are necessary for the repair and 
control of wound healing (13, 14). We speculate that 
the decreased infiltration is a two-edged sword. On 
one side, reduced macrophages/monocytes alleviate 
the  graft-versus-host  disease  (15,  16).  On  the  other, 
reduced  chemoattractants  and  growth  factors  limit 
the migration of endothelial cells and/or endothelial 
progenitor cells, which compromise the angiogenesis. 
Therefore, few vessel-like structures were formed in 
the  healed  tissue  of  CTX  group,  even  in  the 
CTX+hBMSCs group.  
α-SMA  is  a  marker  of  myofibroblasts.  In  the 
present study, co-locolization  of α-SMA and PCNA 
was  found  after  hBMSC  transplantation  suggesting 
the transplanted hBMSCs can differentiate into myo-
fibroblasts  which  also  proliferate  in  the  wound. 
However,  the  expression  of  CD31  is  not  markedly 
increased after CTX treatment and the expression of 
CD146, another marker of endothelial cells, is reduced 
by almost 50%. These results indicate the differentia-
tion of hBMSCs into endothelial cells is suppressed by Int. J. Biol. Sci. 2011, 7 
 
http://www.biolsci.org 
924 
CTX  treatment  but  these  cells  can  differentiate  into 
myofibroblasts.  Moreover,  immunohistochemistry 
and fluorescence staining demonstrate the presence of 
α-SMA  positive  cells  in  the  newly  generated  skins 
suggesting the differentiation of hBMSCs into myofi-
broblasts.  The  myofibroblasts  are  the  main  effector 
cells during the wound healing and the components 
of newly generated skins. 
The results from multipotency induction showed 
impaired  adipogenesis  but  active  osteogenesis.  This 
was similar to previous reports in which adipogenic 
differentiation was blocked by the immunosuppres-
sant (17, 18) and the survival of mesenchymal pro-
genitor cells in the bone marrow during chemother-
apy allowed for osteogenic regeneration (19). 
 
 
Fig.  9.  hBMSCs  differentiate  into  myofibroblasts  and  epithelial  cells.  (a)  Positive  staining  in  the  wound  margin  in 
CTX+Col-I+hBMSCs group. Positive staining of α-SMA in the minor basal cell compartments, glandular-like area of the epi-
dermis and hair follicles other than stroma. (b) Positive staining of MMP-1 in sebaceous glands, hair follicles and epidermis 
in CTX+Col-I group and CTX+Col-I+hfBMSCs group. (c) By double immunostaining, α-SMA and PCNA overlapped in dermal 
stroma, epidermis and hair follicles. Epi=epidermis. D=dermis. PD=papillary layer of dermis. RD=reticular layer of dermis. 
Fo=hair follicle. Int. J. Biol. Sci. 2011, 7 
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The expressions of Col-I and Col-III were signif-
icantly increased after CTX treatment, especially the 
Col-I  expression  was  increased  more  than  13  folds. 
This was consistent with the study of Fathke et al (20) 
in  which  bone  marrow-derived  cells  were  found  to 
transcribe both collagen types I and III, whereas the 
skin-resident cells transcribed only collagen type I. It 
has been reported that delayed administration of CTX 
until 7 days after surgery may produce minimal im-
pairment (21) to the wound healing, and the reduced 
collagen production by dermal fibroblasts is due to 
the adverse effects of irradiation and chemotherapy 
(2). These results indicate the importance of increased 
collagen production by hBMSCs to the acceleration of 
wound  healing.  Moreover,  our  study  showed  in-
creased  expression  of  MMP-1  indicating  collagen 
degradation and, as a result, the Col-I content in the 
healed  tissues  was  reduced  in  CTX+Col-I+hBMSCs 
group and CTX+hBMSCs group. Consistently, MMPs 
play an important role in the remodeling of extracel-
lular  matrix.  They  are  lowly  expressed  in  normal 
adult tissues, but highly expressed under pathological 
conditions, such as wound healing and cancer inva-
sion (22, 23).  
Regenerated  epithelial  cells  and  myofibro-
blasts/fibroblasts  expressing  endothelial  marker 
CD31 are probably differentiated through the mecha-
nism similar to a partial endothelial-to-mesenchymal 
transition (EMT). EMT is initially delineated for the 
cardiovascular development and recently noticed in 
the  various  pathologic  settings,  including  patho-
physiological  vascular  remodeling,  invasion  of  ma-
lignancy and fibrosis. We noticed endothelial marker 
CD31 was colocalized with PCNA in the epidermis, 
hair follicles and dermis. Simultaneously, regenerated 
epithelial  cells  were  also  positive  for  CK14/17/19, 
which has correlation with CD31. This was important 
to the healing as we observed the re-epithelialization 
enhancement  at  the  8th  day  post-transplantation. 
Consistently, in vitro gene expression assays showed 
the significantly increased expressions of CK14/17/19 
after incubation with CTX. Taken together, hBMSCs 
have  the  potential  of  differentiation  into  epithelial 
cells,  and  the  regenerated  cells  simultaneously  ex-
pressing  CKs  and  CD31  verify  the  differentiation 
process through EMT. Moreover, MMP-1 was found 
in the epidermis, hair follicles and sebaceous glands 
of wound margin, which supports the disruption of 
intercellular contacts and cell release from the parent 
epithelial  tissues.  We  also  observed  the  positive 
staining  of  α-SMA  in  regenerated  myofibro-
blasts/fibroblasts. This is consistent with the notion 
that  EMT-derived  cells  are  believed  to  function  as 
fibroblasts in damaged tissue, and may therefore have 
an important role in tissue remodeling and fibrosis. 
These perhaps represent the essential features of EMT 
that  the  resulting  mesenchymal-like  phenotype  is 
suitable for migration. 
Differentiated  myofibroblasts  contribute  to 
wound contraction and positive staining of α-SMA in 
the regenerated epidermis and hair follicles indicates 
a  reverse  epithelial-to-mesenchymal  transition.  We 
only found clearly positive staining of α-SMA in the 
wound bed and margin of the healing tissues in the 
CTX+Col-I+hBMSCs group, however this phenome-
non was not seen in control groups. This result is not 
consistent with that of Fathke et al. in which EGFP+ 
bone marrow cells did not immunostain with muscle 
cell markers suggesting these cells were not differen-
tiating into myofibroblasts although they did appear 
to have a contractile phenotype when placed in vitro. 
We postulate that EMT is not the regular mechanism 
occurring during wound healing in normal condition 
other than those delayed or impaired wound healing. 
Notably, positive staining of α-SMA was observed in 
some  parts  of  epidermis  and  hair  follicles  in  the 
wound margin, which were colocalized with PCNA. 
These findings provide preliminary evidence of epi-
thelial differentiation from hBMSCs, possibly through 
a  reverse  epithelial-to-mesenchymal  transition  (or 
mesenchymal-to-epithelial  transition).Together  with 
the expression of MMP-1, the regenerated epithelial 
cells  contribute  to  re-epithelialization  through  cell 
migration. Similar phenomenon was also reported in 
corneal wound.  
There are still limitations in this study. We did 
not compare the biological features of hBMSCs after 
low-dose and high-dose CTX treatment and the his-
tological analysis was not done after transplantation 
of hBMSCs undergoing treatment of CTX at different 
concentrations. In addition, the specific mechanism of 
the  promoted  wound  healing  after  hBMSC  trans-
plantation is still unclear and should be further inves-
tigated in future studies. 
    Taken  together,  our  results  show  short-term 
high-dose CTX treatment does not significantly affect 
the proliferation of hBMSCs and these cells have sig-
nificant  increase  of  expressions  of  Col-I  and  Col-III 
after this treatment. Moreover, after transplantation of 
high-dose CTX treated hBMSCs, the wound healing is 
significantly  promoted,  especially  at  8  days  after 
transplantation.  
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